<img src="https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7?size=2" nborder="0" align="left" hspace="5" vspace="5" title="22157.jpg" alt="Company Logo"/>Dublin, Aug. 26, 2026 <a href="https://www.globenewswire.com" target="_blank">(GLOBE NEWSWIRE)</a> -- The <a href="https://www.researchandmarkets.com/reports/6263928/global-cereblon-e3-ligase-modulators-celmods?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=tb78qs&amp;utm_campaign=2338044+-+Global+Cereblon+E3+Ligase+Modulators+(CELMoDs)+Market+Report+2026+%7c+Provides+In-Depth+Clinical%2c+Competitive%2c+and+Commercial+Intelligence&amp;utm_exec=jocamsai" rel="nofollow" target="_blank" title="Global Cereblon E3 Ligase Modulators (CELMoDs) Clinical Trials &amp; Market Opportunity Insight 2026">"Global Cereblon E3 Ligase Modulators (CELMoDs) Clinical Trials &amp; Market Opportunity Insight 2026"</a> has been added to ResearchAndMarkets.com's offering. Report Highlights: <ul><li>Comprehensive research methodology and market assessment</li><li>First Cereblon E3 ligase modulator drug anticipated by 2030</li><li>Commercial relevance of CELMoD therapies in oncology</li><li>Analysis of more than 20 CELMoD drugs in clinical development</li><li>Clinical trial insights by company, country, indication, and development phase</li><li>Key clinical study initiation and completion timelines</li><li>Current development landscape and future market opportunities</li><li>Competitive analysis of pharmaceutical and biotechnology companies</li></ul> Growing Need for CELMoD-Targeting Therapies The global Cereblon E3 Ligase Modulators market has developed into an advanced clinical-stage segment within targeted protein degradation and immuno-oncology. CELMoD drug candidates are designed to enhance cereblon-mediated protein degradation with greater potency and selectivity than earlier immunomodulatory agents. Their activity against transcription factors such as IKZF1 and IKZF3 supports immune activation and antitumor responses, particularly in hematologic malignancies such as multiple myeloma. As of June 2026, no CELMoD therapy had received full regulatory approval. However, the clinical pipeline is approaching a pivotal stage, led by candidates including iberdomide, mezigdomide, and golcadomide. Development programs increasingly evaluate CELMoDs in combination with monoclonal antibodies, proteasome inhibitors, corticosteroids, and other established oncology therapies. Iberdomide has become particularly important to the advancement of the drug class, supported by late-stage studies in relapsed or refractory multiple myeloma. Thereport provides pharmaceutical companies, biotechnology firms, investors, researchers, and other industry stakeholders with a structured analysis of scientific innovation, clinical development, competitive positioning, and commercialization strategies. It also examines how emerging clinical evidence could influence the future adoption of CELMoD therapies across global oncology markets. CELMoD Clinical Trials and Pipeline Insights CELMoD clinical research remains concentrated in hematologic cancers, particularly relapsed and refractory multiple myeloma, where substantial unmet medical need persists. Current trials are assessing monotherapy and combination regimens across multiple treatment lines. Combination strategies are intended to strengthen immune activity, improve response durability, and address resistance associated with established therapies. Beyond multiple myeloma, CELMoD candidates are being investigated in lymphomas, other hematologic malignancies, and selected solid tumors, including renal cell carcinoma. Although blood cancers account for most pipeline activity, exploratory programs demonstrate the broader potential of cereblon-mediated protein degradation. Adaptive trial designs, biomarker-selected cohorts, and precision oncology strategies are also becoming increasingly prominent within CELMoD clinical development. The report evaluates more than 20 CELMoD drug candidates and provides clinical trial segmentation by company, geography, indication, and phase. It also reviews major study initiation and completion dates, enabling stakeholders to identify potential regulatory milestones, competitive inflection points, and commercialization opportunities. Leading Companies in CELMoD Research and Development Bristol Myers Squibb holds a leading position in the CELMoD clinical pipeline, with programs involving iberdomide, mezigdomide, golcadomide, and additional early-stage compounds. Iberdomide is being studied across multiple treatment settings, reflecting a broader strategy to incorporate cereblon modulation into established oncology regimens and potential future standards of care. Biotechnology companies are also contributing to the competitive landscape. C4 Therapeutics and other developers are advancing next-generation cereblon modulators and molecular glue degraders intended to expand the range of addressable protein targets. Strategic partnerships involving computational biology, artificial intelligence, omics platforms, and specialized drug development capabilities are expected to accelerate target identification and candidate optimization. Future CELMoD Market Opportunities Future CELMoD research is expected to extend beyond established transcription-factor targets toward a wider range of disease-associated proteins. Advances in cereblon modification, molecular glue technology, artificial intelligence, and multi-omics research may support the discovery of new degradation pathways and broaden potential therapeutic applications. Combination regimens are likely to remain central to CELMoD development, including evaluation in earlier treatment lines. As clinical evidence matures, selected candidates could become integrated with immuno-oncology agents, targeted therapies, and existing multiple myeloma treatment platforms. Biomarker-based patient selection may further improve clinical outcomes and support precision medicine strategies. With a pipeline of more than 20 drugs, expanding industry investment, and multiple late-stage clinical programs, the global CELMoD market represents an emerging opportunity in targeted protein degradation. This report provides the clinical, competitive, and commercial intelligence required to assess the market's development through 2030 and beyond. Key Topics Covered 1. Research Methodology 2. Introduction to Cereblon E3 Ligase Modulators (CELMoDs) 2.1 Overview of Targeted Protein Degradation (TPD) Landscape 2.2 Evolution of CRBN Based Therapeutics (IMiDs to CELMoDs) 2.3 Market Relevance &amp; Unmet Needs in Oncology &amp; Beyond 3. Basics of Cereblon E3 Ligase Modulators (CELMoDs) Biology 3.1 Definition &amp; Core Concept of CELMoDs 3.2 CRBN Complex &amp; Protein Degradation Pathway (Ubiquitin-Proteasome System) 3.3 Positioning Within TPD: IMiDs vs CELMoDs vs PROTACs 4. Mechanism of Action &amp; Drug Class Characteristics 4.1 CRBN Mediated Molecular Glue Mechanism 4.2 Target Protein Degradation &amp; Downstream Effects 4.3 Therapeutic Outcomes &amp; Resistance Mechanisms 5. Global Cereblon E3 Ligase Modulators (CELMoDs) Market Overview 5.1 Current Clinical Development &amp; Market Scenario 5.2 Future Market Outlook 6. Cereblon E3 Ligase Modulators (CELMoDs) - Clinical Development Trends by Indication 6.1 Cancer 6.1.1 Hematological Malignancies 6.1.2 Solid Cancers 6.2 Hematological Disorders 6.3 Autoimmune &amp; Inflammatory Diseases 6.4 Microbial Infections 7. Cereblon E3 Ligase Modulators (CELMoDs) Development Analysis by Region 7.1 US 7.2 Europe 7.3 China 8. Global Cereblon E3 Ligase Modulators (CELMoDs) Clinical Trials Overview 8.1 By Phase 8.2 By Country 8.3 By Company 8.4 By Indication 9. Global Cereblon E3 Ligase Modulators (CELMoDs) Clinical Trials Insight by Company, Country, Indication &amp; Phase 9.1 Preclinical 9.2 Phase I 9.3 Phase I/II 9.4 Phase II 9.5 Phase III 9.6 Preregistration 10. Global Cereblon E3 Ligase Modulators (CELMoDs) Market Dynamics 10.1 Market Drivers &amp; Opportunities 10.2 Challenges &amp; Strategic Solutions 11. Competitive Landscape 11.1 BioTheryX 11.2 Bristol Myers Squibb 11.3 C4 Therapeutics 11.4 Chia Tai Tianqing Pharmaceutical Group 11.5 Decoy Therapeutics 11.6 Degron Therapeutics 11.7 Evotec 11.8 GluBio Therapeutics 11.9 Gluetacs Therapeutics 11.10 Kangpu Biopharmaceuticals For more information about this report visit <a href="https://www.researchandmarkets.com/reports/6263928/global-cereblon-e3-ligase-modulators-celmods?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=tb78qs&amp;utm_campaign=2338044+-+Global+Cereblon+E3+Ligase+Modulators+(CELMoDs)+Market+Report+2026+%7c+Provides+In-Depth+Clinical%2c+Competitive%2c+and+Commercial+Intelligence&amp;utm_exec=jocamsai" rel="nofollow" target="_blank" title="">https://www.researchandmarkets.com/r/juxz0k</a> About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. <pre>CONTACT: 
CONTACT: ResearchAndMarkets.com 
 Laura Wood,Senior Press Manager 
 press@researchandmarkets.com
 For E.S.T Office Hours Call 1-917-300-0470 
 For U.S./ CAN Toll Free Call 1-800-526-8630 
 For GMT Office Hours Call +353-1-416-8900 

</pre> <img alt="" src='https://ml.globenewswire.com/media/YjM2Y2I0MjYtNDFlYi00MDU5LWI1YWEtMzhmMjlkMjY4MGQyLTEwMjY3MzctMjAyNi0wOC0yNi1lbg==/tiny/Research-and-Markets.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

Global Cereblon E3 Ligase Modulators (CELMoDs) Market Report 2026 | Provides In-Depth Clinical, Competitive, and Commercial Intelligence

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn